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Chronic γ-herpesvirus infection is a dynamic process involving latent infection, reactivation from latency, and low level persistent replication.
The γ-herpesviruses maintain latent infection in restricted subsets of hematopoietic cells as a result of an intricate balance between host factors that
suppress infection and viral factors that facilitate evasion of the immune response. Immune effectors limit reactivation and subsequent replication
events, and the adaptive immune response ultimately restricts infection to a level compatible with life-long infection. However, it has not been
possible to determine whether the immune system constrains chronic infection by directly targeting latently infected cells in vivo due to the
complex nature of chronic infection. To begin to address this issue, we generated a murine γ-herpesvirus 68 (γHV68) deficient in its ability to
replicate or undergo reactivation from latency via a mutation in the single-stranded DNA binding protein encoded by ORF6. Even in the absence
of lytic replication, this virus established long-term infection in peritoneal cells of wild-type mice at levels identical to that of wild-type γHV68,
and generated an immune response that was sufficient to protect against secondary challenge with wild-type γHV68. Nevertheless, the number of
latently infected cells was not significantly altered in mice deficient in T cells or both T cells and B cells, demonstrating that the adaptive immune
system is incapable of altering infection with a virus lacking the capacity for lytic replication and reactivation from latency. Thus, these data
support the conclusion that latency is immunologically silent.
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Herpesvirus infection is biphasic, characterized by lytic
replication during the acute phase and the establishment of
latency during the chronic phase. An important component ofAbbreviations: γHV68, murine γ-herpesvirus 68; EBV, Epstein–Barr virus;
HSV, herpes simplex virus.
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lytic replication of virus (Simas et al., 1998, 1999; Clambey et
al., 2000), a process we term persistent replication (Gangappa et
al., 2002a, 2002b; Tibbetts et al., 2002). Virus derived from
reactivation and persistent replication events may contribute to
the maintenance of long-term latency in new host cells as well
as facilitate spread to new hosts (Gangappa et al., 2002a,
2002b). Thus, chronic infection is a dynamic process consisting
of latently infected cells, reactivation events, and persistent
replication.
The α-, β-, and γ- herpesvirus subfamilies share homology
in genes essential for lytic replication and exhibit similar lytic
replication mechanisms, but their strategies for establishing
latent infection differ significantly. Because the γ-herpesviruses
latently infect hematopoietic cells including lymphocytes,
vascular cells, and epithelial cells, and are associated with the
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the complex interplay between chronic γ-herpesvirus infection
and the immune system is of critical importance. In particular,
understanding the relationships between lytic replication and
latency, and between latency and the immune system, is
paramount to defining rational strategies to prevent or treat
these viruses.
Two fundamental questions have lingered regarding this
complex relationship. First, does the establishment of latency
require lytic replication during acute infection? It has long been
considered likely that acute replication is required for efficient
establishment of γ-herpesvirus latent infection, but there has
been little evidence that directly addresses this relationship in
vivo due to the difficulty in distinguishing these two phases of
infection. Lytic replication might be important for dissemination
of the virus through the host, for establishment of long-term
stable carriage of the viral genome in latently infected cells, for
continuous re-seeding of the latent pool as a consequence of
persistent replication, or for all of the above. We have
previously demonstrated that the establishment of latency by
murine γ-herpesvirus 68 (γHV68) is independent of both route
of infection (intraperitoneal versus intranasal) and dose of
infection (10−1 to 106 PFU) (Tibbetts et al., 2003a, 2003b). This
work suggested that the establishment of latency is a very
efficient process that does not require robust viral replication
early after infection, but did not directly address whether lytic
replication was required for the establishment of latency.
The generation of replication-defective viruses by several
groups has facilitated further examination of this and other
questions regarding the physiology of long-term infection and
the ability of the immune system to regulate that infection.
Recently, Flano et al. used a replication-defective γHV68
mutant (Jia et al., 2004) to demonstrate that following high dose
intraperitoneal administration, viral genome can be detected in
splenic B cells, albeit at a significantly lower level than after
administration of wild-type virus (Flano et al., 2005). This
intriguing result shows that replication is not a requirement for a
γ-herpesvirus to establish long-term infection in vivo but also
suggests that replication is a requirement for efficient
establishment of normal levels of infection in the spleen.
(Note: for the purpose of this discussion, we make a distinction
between “latency” and “long-term infection” since latency by
definition requires the capacity to reactivate, a process that
cannot occur without complementation if a virus is fully
replication-defective.) Similarly, Moser et al. used intranasal
administration of a γHV68 mutated in gene 50 (a key
transcriptional activator; Wu et al., 2000) to demonstrate
establishment of long-term infection in lung B cells in the
absence of lytic replication (Moser et al., 2006).
A second fundamental question that has not yet been
answered is whether the immune system directly restricts the
level of latently infected cells in vivo. It is clear that the immune
system is important for limiting the reactivation and subsequent
replication events that occur during chronic infection, and that
the immune system can regulate the frequency of cells carrying
latent viral genome (for example references, Tibbetts et al.,
2002; Christensen et al., 1999; Flano et al., 2005; Usherwood etal., 2000; Stevenson et al., 2002). However, these data do not
directly address whether the regulation of latency (i) occurs via
direct effects on latently infected cells (cells that are carrying the
viral genome in the absence of lytic infection), or (ii) is
secondary to immune suppression of viral reactivation or
persistent replication, which in turn hinders re-seeding of latent
pools. The initial results from Moser et al. raise the possibility
that the gene 50-deficient replication-defective γHV68 is able
to persist during long-term infection because of a lack of
recognition by the immune system, since this virus failed to
prime an immune response and failed to protect against
challenge with wild-type virus. However, the question of
whether the immune system can directly target this type of
infection has yet to be answered.
In work described here, we examine the dynamics of chronic
infection using a newly constructed mutant γHV68 that is fully
replication-defective, and address the hypothesis that the
immune system directly restricts cells harboring viral genome.
We confirm that the establishment of γHV68 infection does not
require lytic viral replication, and extend this observation by
demonstrating that replication-defective γHV68 establishes
long-term infection in peritoneal cells at levels similar to
wild-type γHV68 and induces an effective immune response.
We further demonstrate that, in the absence of reactivation and
persistent replication, T cells and B cells do not alter the
frequency of cells harboring viral genome, suggesting that
latency itself may be immunologically silent.
Results and discussion
Generation of a mutant γHV68 deficient in the ssDNABP
To independently study the lytic and latent phases of
α-herpesvirus infection, several groups have generated herpes
simplex virus (HSV)-1 mutants that are deficient in their ability
to replicate due to a mutation or deletion of genes required for
viral DNA replication. Mutations in genes encoding compo-
nents of the HSV-1 replication machinery prevent viral DNA
replication both in vitro and in vivo. The HSV-1 single-stranded
DNA binding protein (ssDNABP) ICP8 (encoded by UL29) has
been shown by numerous groups to be an important component
of the viral replication process. ICP8 was initially identified as a
DNA binding protein (Bayliss et al., 1975; Powell and Purifoy,
1976) that preferentially binds to single stranded DNA (Lee and
Knipe, 1985), and was later shown to play an important role in
viral DNA synthesis. Studies using mutant viruses indicated
essential roles for ICP8 in DNA synthesis (Weller et al., 1983)
and viral replication (Littler et al., 1983), and for maintaining
the highly ordered cascade of viral gene expression that occurs
during the later stages of acute replication (Godowski and
Knipe, 1986). A few reports have also demonstrated the
essentiality of some γ-herpesvirus replication proteins, includ-
ing the ssDNABP of Epstein–Barr virus (BALF2) (Fixman et
al., 1992).
Based on the preponderance of data demonstrating a role for
ICP8 in lytic replication, and the similarities between lytic
machinery among the herpesvirus subfamilies, we hypothesized
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replication. In support of this, two groups recently used
transposon mutagenesis approaches to show that the γHV68
ORF6 (which encodes the ssDNABP) is essential for lytic
replication of γHV68 (Moorman et al., 2004; Song et al., 2005).
Thus, we used bacterial artificial chromosome (BAC) technol-
ogy to generate a virus with a specific mutation in ORF6. Virus
derived from a full-length γHV68 genome cloned as a bacterial
artificial chromosome (γHV68 BAC) replicates normally and
establishes levels of latency comparable to wild-type virusFig. 1. Construction and analysis of γHV68.ΔssDNABP. (A) Schematic of the M3 t
γHV68 sequence altered during construction, and the resulting changes in the γHV68
of γHV68 and γHV68.ΔssDNABP BAC plasmid DNA. DNA was digested with
electrophoresis followed by Southern blot. Blots were probed with 32P-labeled γHV6
ORF8 region of the genomes are represented in the schematic. Southern blot revealed
PCR assay validation. Nested PCR was used to detect wild-type γHV68 (wild-typeO
using PCR primers specific for ORF6-one set complementary to the 5′ end of ORF6 (
set complementary to an inner region of ORF6 (primer set B: outer ccattgtcctttaga
nested PCR primers specific for the mutated region of the genome, including primer s
C: outer gaacaagtctggaaagaaatgc, inner taccaggatcttgccatcctat). PCR assays were vali
a background of 10,000 uninfected cells, as has been described for other regions of t
represent the number of positive reactions/number of total reactions. Thus, these as
γHV68.ΔssDNABP genome in 10,000 cells. There were a total of 4 false positives(Adler et al., 2000). Although the γHV68 BAC virus is slightly
attenuated for ex vivo reactivation from latently infected
splenocytes, wild-type levels of reactivation are restored after
excision of the BAC sequences (Adler et al., 2001). We used
allelic exchange (Smith and Enquist, 1999) to create a mutation
in the ssDNABP (encoded by the 3312 bp ORF6) within the
γHV68 BAC. Specifically, a Kanamycin cassette (derived from
pET-30a) flanked by NheI sites was inserted 121 bp down-
stream (nt 11327) of the start codon of ORF6 (Fig. 1A). This
insertion resulted in a 5 bp deletion (nts 11327–11332), ao ORF8 region of the γHV68 and γHV68.ΔssDNABP genomes. The wild-type
.ΔssDNABP sequence (as described in the text) are underlined. (B) Southern blot
HindIII, NheI and SacII, or NheI and SalI, and then subjected to agarose gel
8 BAC DNA and exposed to autoradiography film. Restriction sites in theM3 to
the presence of appropriate sized bands in the mutant viral genome. (C) Nested
RF6) versus γHV68.ΔssDNABP (mutant ORF6). Wild-typeORF6was detected
primer set A: outer gaagtgctgactcggcgtgg, inner ctctgcttttggacactcatcatg) and one
agcatcagg, inner gtattttgtaggcttaacggtcagag). Mutant ORF6 was detected using
et A and one set complementary to an inner region of the Kan cassette (primer set
dated using 10 copies, 1 copy, or no copies of the corresponding plasmid DNA in
he γHV68 genome (Tibbetts et al., 2003a, 2003b; Weck et al., 1999). Numbers
says were capable of efficiently detecting as little as 1 copy of the γHV68 or
in 160 reactions for a 2.5% false positive rate.
213S.A. Tibbetts et al. / Virology 353 (2006) 210–219frameshift, and a premature stop mutation in ORF6. Following
sucrose selection, positive clones were amplified, and purified
DNAwas subjected to Southern blot analysis to verify both the
presence of the mutation and the integrity of the entire viral
genome. One γHV68 BAC mutant (γHV68.ΔssDNABP) with
both the correct mutation and an otherwise intact genome was
selected for use (Fig. 1B).
γHV68.ΔssDNABP virus is deficient in replication
Transfection of wild-type γHV68 DNA or wild-type BAC
DNA into 3T12 fibroblast cells results in the production of
infectious virus and cytopathic effect (Fig. 2A). In contrast,
transfection of γHV68.ΔssDNABP BAC DNA into 3T12 cells
did not result in cytopathic effect (Fig. 2B). Furthermore,
transfected cells did not produce infectious virus since transfer
of cell lysate or supernatant fluid to 3T12 cells did not result in
cytopathic effect (data not shown). Thus, mutation of the
ssDNABP within the γHV68 BAC resulted in a viral genome
that was deficient in its ability to replicate normally.
To facilitate production of infectious virus for further
studies, we transduced 3T12 cells with a retrovirus (van
Parijs et al., 1999) engineered to express a full-length copy
of γHV68 ORF6 and a GFP element, and FACS sorted for
cells expressing GFP. The resulting bulk cell line, called
3T12.ORF6, maintained GFP expression after long-term
culture, and expressed a polypeptide whose molecular mass
was identical to that predicted for the ORF6 protein, as
determined by Western blot using polyclonal antisera from
γHV68-infected mice (data not shown). In contrast to
parental 3T12 cells, transfection of 3T12.ORF6 cells with
γHV68.ΔssDNABP DNA resulted in cytopathic effect (Fig.
2C). Thus, complementation of the ssDNABP mutation with
ORF6 allowed production of infectious virus. When
supernatant fluid from these cultures was transferred to
wild-type 3T12 cells, we did not observe CPE (Fig. 2D),
demonstrating that γHV68.ΔssDNABP was replication-
defective, and that contamination with revertant virus was
not detectable. γHV68.ΔssDNABP stock virus was produced
by amplification on the 3T12.ORF6 complementing cell line
for two rounds, and was assessed for the absence of
revertant virus, as discussed below.Fig. 2. Cytopathicity induced by γHV68.ΔssDNABP versus wild-type γHV68. Pho
were transfected with BAC plasmid DNA and monitored for cytopathic effect 5 to 8 da
with γHV68.ΔssDNABP BAC, (C) 3T12.ORF6 cells transfected with γHV68.Δs
γHV68.ΔssDNABP BAC DNA was transferred to 3T12 cells, and cells were mon
experiments per condition.We next developed an assay to quantify infectious
γHV68.ΔssDNABP. Plaque formation on the complementing
cell line 3T12.ORF6 was inconsistent and inefficient. We
therefore developed a tissue culture infectious dose (TCID50)
assay. 3T12.ORF6 cells were subcloned, and clones were
screened after infection with γHV68.ΔssDNABP for ability to
generate GFP expressing foci coincident with viral cytopathi-
city. Permissive infected cells expressed high levels of GFP after
infection (significantly above background levels) due to the
presence of a GFP cassette engineered into the parental γHV68
BAC (Adler et al., 2000). The most permissive clones, as
detected by the number and size of GFP foci, expressed the
highest levels of ORF6 protein by Western blot (data not
shown). One clone was expanded and seeded into 96 well plates
for TCID50 assays. Serial 10-fold dilutions of γHV68 and
γHV68.ΔssDNABP were added (12 wells per dilution) and
formation of GFP foci was assessed 4 days after inoculation.
Based on the detection of virus-induced GFP foci in these cloned
cells, we assigned a TCID50 titer to the γHV68.ΔssDNABP
viral stock using the method of Karber (Karber, 1931).
Comparing the TCID50 assay to the standard plaque assay for
wild-type γHV68, 1000 PFU of wild-type γHV68 corre-
sponded to approximately 1800 TCID50. This demonstrates that
the TCID50 assay was nearly as sensitive as the standard γHV68
plaque assay employed in earlier studies.
Using sensitive in vitro and in vivo assays, we confirmed that
γHV68.ΔssDNABP was replication-defective as well as free of
revertant virus. Infection of wild-type mouse embryo fibroblasts
in vitro generated no cytopathic effect (data not shown).
Infection of 10 T and B cell deficient RAG−/− mice with 1000
TCID50 γHV68.ΔssDNABP did not result in lethality even
after 6 months (data not shown). In comparison, as little as
100–400 PFU of wild-type γHV68 administered either
intraperitoneally or intranasally is lethal for 100% of RAG−/−
mice after 35 days (Sparks-Thissen et al., 2004; Braaten et al.,
2005). Anti-γHV68Western blots of lysates from infected 3T12
cells demonstrated significantly reduced viral protein produc-
tion in cells infected with γHV68.ΔssDNABP as compared to
cells infected with wild-type virus (data not shown). Together
these data confirm that ORF6 is an essential gene (Moorman et
al., 2004; Song et al., 2005), and further demonstrate that
γHV68.ΔssDNABP is replication-defective. While it istographs (40×) depict fibroblast monolayers. (A–C) 3T12 or 3T12.ORF6 cells
ys later. (A) 3T12 cells transfected with γHV68 BAC, (B) 3T12 cells transfected
sDNABP BAC. (D) Supernatant fluid from 3T12.ORF6 cells transfected with
itored for cytopathic effect for 8 days. The data are representative of at least 3
Fig. 3. Ex vivo viral genome frequency of γHV68.ΔssDNABP versus wild-type
γHV68. Limiting dilution nested PCR for viral genomes in peritoneal cells
harvested from B6 mice at 16 or 42 dpi. Mice were infected i.p. with 1000 TCID
γHV68.ΔssDNABP or 1000 PFU γHV68. Peritoneal cells were harvested at 16
dpi and 42 dpi, and subjected to limiting dilution nested PCR (12 wells per
dilution) using the assay described in Fig. 1C. x axis represents the number of
cells per reaction. y axis represents the percentage of reactions that were positive
for viral genome. The frequency of cells harboring viral genome (as stated in the
text) was determined at 63.2% (indicated by the dashed line) using Poisson
distribution. The data are pooled from 2 to 4 independent experiments, 5 mice
per sample group per experiment. γHV68.ΔssDNABP genome was not detected
in mice infected with γHV68 (not shown). γHV68 genome was not detected in
mice infected with γHV68.ΔssDNABP (not shown).
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occur during passage in complementing cells, the frequency of
this event was undetectable in in vitro assays and following
infection of immunodeficient mice. We therefore reasoned that
the γHV68.ΔssDNABP stock would be useful for in vivo
studies.
A replication-defective γ-herpesvirus can establish long-term
infection in vivo
To determine whether γHV68 could establish infection
independent of acute replication, we delivered 1 × 103 TCID50
γHV68.ΔssDNABP virus intraperitoneally (i.p.) to wild-typeFig. 4. Ex vivo viral genome frequency of γHV68.ΔssDNABP in B6 mice versus imm
cells harvested from wild-type B6 mice, or from MHC class II−/−, TCRβδ−/−, or
γHV68.ΔssDNABP. Peritoneal cells were harvested at 42 dpi, and frequency of ce
nested PCR as described for Fig. 3. The data are pooled from 2 to 5 independent ex
significant differences between sample groups in these experiments by students t teC57BL/6J (B6) mice and measured the frequency of peritoneal
cells and splenocytes carrying viral genome at 16 days
postinfection (dpi). Peritoneal cells and splenocytes are both
primary reservoirs for virus during wild-type γHV68 infection
via intraperitoneal or intranasal inoculation (Tibbetts et al.,
2003a, 2003b; Sunil-Chandra et al., 1992). To detect infection,
we developed an assay capable of detecting a single copy of the
γHV68.ΔssDNABP genome in a cell (Fig. 3). Similar assays
have been standardly used to quantify the frequency and
number of cells carrying latent γHV68 genomes (e.g. Flano et
al., 2005; Gangappa et al., 2002a, 2002b; Kapadia et al., 1999).
Using PCR primers specific for γHV68.ΔssDNABP, we
detected viral genome in 1 out of 1800 peritoneal cells at
16 dpi (Fig. 4). This was not due to revertant virus since this
PCR assay detects only γHV68 genomes containing the ORF6
mutation (see Fig. 1C). A similar frequency of cells carried viral
genome at 42 dpi (1 out of 2900). These levels were particularly
striking because they were nearly identical to the levels of
latency achieved by wild-type γHV68 following infection of B6
mice (1 out of 2400), and did not appreciably change between 2
weeks and 6 weeks postinfection. Although attenuation of
γHV68 BAC virus for frequency of cells carrying viral genome
has not previously been demonstrated, it is notable that γHV68
carrying BAC sequences is slightly attenuated for ex vivo
reactivation from splenocytes (Adler et al., 2001). Thus, it is
conceivable that removal of BAC sequence from the
γHV68.ΔssDNABP virus could result in an even higher level
of infection. However, we feel it is appropriate to conclude that
replication is not required for establishment of long-term
infection since there is no evidence to suggest that the BAC
sequences themselves could permit a virus to establish long-
term infection.
To determine whether the observation of stable carriage of
genome in peritoneal cells was due to previously undetected
revertant virus present in the γHV68.ΔssDNABP stock, we
developed a PCR assay to detect wild-type ORF6. In control
experiments, this assay detected 1 copy of ORF6 in a
background of 10,000 uninfected cells 14 of 24 times, and 10
copies of ORF6 in a background of uninfected cells 21 of 22unodeficient mice. Limiting dilution nested PCR for viral genomes in peritoneal
RAG−/− mice on B6 backgrounds. Mice were infected i.p. with 1000 TCID
lls harboring γHV68.ΔssDNABP genome was determined by limiting dilution
periments, 5 mice per sample group per experiment. There were no statistically
st (P = 0.14 for CII−/−, P = 0.10 for TCRβδ−/−, P = 0.06 for RAG).
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are sufficient to establish latent infection in peritoneal cells at a
frequency of 1/600 (Tibbetts et al., 2003a, 2003b), this assay
was sufficiently sensitive to detect 0.01% contamination with
revertant virus.
Importantly, wild-type ORF6 DNA could not be detected in
mice infected with γHV68.ΔssDNABP (data not shown),
demonstrating that selection and expansion of viruses with a
wild-type ORF6 locus had not occurred during establishment of
long-term infection in vivo. Additionally, ex vivo reactivation
from peritoneal cells was not detected after infection with
γHV68.ΔssDNABP (data not shown), an observation that is
consistent with the conclusion that cells we detected in these
mice were carrying replication-defective viral genome rather
than revertant virus genome. Thus, these data demonstrate that a
replication-defective γ-herpesvirus can establish long-term
infection in peritoneal cells at levels equivalent to wild-type
γHV68. These data parallel studies demonstrating that a γ-
herpesvirus can establish long-term infection in splenocytes or
lung B cells in the absence of lytic replication (Flano et al.,
2005; Moser et al., 2006).
Notably, γHV68.ΔssDNABP genome was not detected in
splenocytes following i.p infection (data not shown). To
determine whether this effect was related to route of delivery,
we infected wild-type mice intranasally with 1000 TCID50 of
γHV68.ΔssDNABP; however, viral genome was similarly
undetectable in the spleen in these experiments. It is
conceivable that a larger dose of virus would be sufficient to
partially overcome this deficit. This possibility is supported by
the recent demonstration that the ORF31-deficient, replication-
defective γHV68 is detectable in the spleen following high dose
(7.5 × 105 PFU) i.p. administration, but only at levels
significantly below that of wild-type virus (Flano et al.,
2005). Thus, we conclude that lytic replication is required for
efficient establishment of chronic infection in the spleen but not
in peritoneal cells. Further testing will be necessary to determine
whether this relates to a difference in the ability of replication-
defective γ-herpesviruses to infect macrophages versus B cells
(the primary latently infected cellular constituents of the
peritoneum and the spleen, respectively), or whether it is a
reflection of dysfunctional trafficking of the virus.
We currently do not know whether the long-term carriage of
γHV68 genome in the absence of the capacity to replicate
represents a state molecularly similar to true latency. It will be
important to determine (i) the form that replication-defective
genomes maintain during infection in different cell types, since
latent genomes are typically episomal in the course of wild-type
infection, and (ii) whether these genomes are transcriptionally
active. Further, it will be essential to determine whether genes
expressed during this type of infection reflect a pattern of
latency or of abortive lytic infection.
Adaptive immunity does not regulate the level of
replication-defective virus in vivo
The important role of adaptive immunity in regulation of
chronic γ-herpesvirus infection is clear from studies demon-strating that the frequency of cells that carry EBV genome
during latency is increased in immunosuppressed patients
(Babcock et al., 1999). Several groups have also demonstrated
that CD4 and CD8 Tcells restrict chronic γHV68 infection (e.g.
Tibbetts et al., 2002; Stevenson et al., 1999; Ehtisham et al.,
1993; Usherwood et al., 2000; Braaten et al., 2005; Sparks-
Thissen et al., 2004; Cardin et al., 1996; Christensen et al.,
1999), data that are consistent with an important role for T cells
in altering or eliminating latently infected cells. The strongest
data for an ongoing role for T cells in immune regulation of
γHV68 latency are studies showing that in vivo depletion of
both CD4 and CD8 T cells after establishment of latency
increases the frequency of cells that reactivate from latency after
explantation (McClellan et al., 2004). However, interpretation
of these data is complicated by the fact that chronic infection is a
dynamic process that likely involves latency, reactivation, and
persistent replication of virus derived from reactivation events
(Gangappa et al., 2002a, 2002b). Thus, the use of a replication-
defective γHV68 in these types of studies may aid in
understanding this complex relationship.
Several groups have generated and tested immune responses
to replication-defective HSV-1 mutants. These viruses induce T
cell responses and neutralizing antibody responses that are
strong enough to reduce challenge virus latency and acute
replication (Augustinova et al., 2004; Morrison and Knipe,
1994; Nguyen et al., 1992). Although these data illustrate the
potential immunogenicity of replication-defective herpes-
viruses, no study has directly tested the ability of the immune
system to alter infected cells in vivo in the absence of priming
by lytic viral antigens. Specifically, the hypothesis that T cells
directly eliminate or restrict the expansion of infected cells in
vivo has not been unequivocally addressed using a virus devoid
of reactivation and persistent replication. Therefore, we used
γHV68.ΔssDNABP infection as a model to determine whether
T cells could restrict γ-herpesvirus infection in the absence of
lytic replication.
Previous studies demonstrating the importance of CD4 and
CD8 Tcells in regulation of latent infection, including studies in
MHC Class II-deficient mice and CD8 Tcell-deficient mice (see
above), and studies in the context of vaccination (McClellan
et al., 2004; Tibbetts et al., 2002, 2003a, 2003b), have shown
significant effects of immune deficiency on γHV68 latency by
42 dpi. We therefore examined whether the frequency of cells
carrying replication-defective γHV68 genomes was altered in
mice deficient in components of the adaptive immune response
at 42 days after infection. We infected wild-type B6 mice, CD4
T cell-deficient mice lacking MHC Class II (Grusby et al.,
1991), CD4 and CD8 T cell-deficient TCRβδ−/− mice
(Mombaerts et al., 1992a, 1992b), and CD4 and CD8 T cell
and B cell-deficient RAG−/− mice (Mombaerts et al., 1992a,
1992b) with γHV68.ΔssDNABP.
Strikingly, the frequency of cells bearing viral genome in
these different immunodeficient mice was the same as that
observed in wild-type mice (Fig. 4). Although the frequency in
Class II-deficient was slightly elevated (1/1500) compared to
wild-type mice (1/2900), this was not statistically significant
(P > 0.10). Frequencies in TCRβδ−/− mice (1/5000; P > 0.10)
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that in B6 mice. Thus, even in the absence of all T and B cells,
the frequency of viral genome bearing cells at 42 dpi was not
significantly altered. The data that mice lacking all T and B cells
could sustain long-term infection with γHV68.ΔssDNABP is
consistent with earlier work demonstrating that wild-type
γHV68 can establish infection in mice deficient in B cells
(Weck et al., 1996). Viral genome was not detected in
splenocytes of T cell-deficient mice at either time point,
demonstrating that the lack of detectable infection by
γHV68.ΔssDNABP at this site in wild-type mice is not
mediated by T cells. Together these data demonstrate that, in
the absence of lytic replication and reactivation in vivo, T cells
and B cells do not directly control the frequency of cells
carrying γHV68.ΔssDNABP genome.
It was possible that the lack of immune control of the number
of cells carrying γHV68.ΔssDNABP genome was due to (i) an
inability of this virus to prime the immune response, or (ii) the
evasion of immune cell targeting. Several groups have
previously demonstrated that the administration of attenuated
viruses primes both T cell and B cell responses and is thus an
effective means of vaccinating against acute γ-herpesvirus
infections (Tibbetts et al., 2003a, 2003b; Da Costa et al., 1999;
Morrison and Knipe, 1997; Weibel et al., 1984; MacDonald et
al., 1998). However, a γHV68 mutant deficient in gene 50 could
not protect against challenge with wild-type virus (Moser et al.,
2006). To determine whether the observed lack of immune
control of γHV68.ΔssDNABP infection was due to inefficient
priming, we used γHV68.ΔssDNABP to vaccinate against a
challenge with wild-type γHV68. We reasoned that if
γHV68.ΔssDNABP stimulated the immune system it would
effectively vaccinate against acute infection. B6 mice were
inoculated i.p. with 3T12 cell lysate (mock), 1000 TCID50
γHV68.ΔssDNABP, or 1000 PFU wild-type γHV68. After
28 days, all mice were challenged i.n. or i.p. with 1000 PFU
wild-type γHV68. Fourteen days later, spleens were harvested
and acute titers were determined by plaque assay (Fig. 5). The
mean titer of mice that were mock vaccinated was
2.7 × 102 PFU/ml after i.n. challenge and 2.6 × 102 PFU/mlFig. 5. Acute titers of γHV68 challenge virus following vaccination with γHV68.Δss
after challenge with wild-type γHV68. Mice were inoculated i.p. with medium alone
days later, all groups were challenged i.n. or i.p. with 1000 PFU γHV68. After 14 d
plaque assay of spleen suspensions on 3T12 fibroblast monolayers. The data are poo
challenge. The dashed line indicates the limit of detection, 50 PFU/ml.after i.p. challenge, similar to the level of acute titers previously
demonstrated following low dose infection (Tibbetts et al.,
2003a, 2003b). Little or no titer was detectable in spleens from
mice immunized with γHV68.ΔssDNABP (limit of detection
was 50 PFU/ml), which is comparable to titers observed in mice
immunized with wild-type γHV68. Thus, vaccination with
γHV68.ΔssDNABP generated a protective immune response
similar to that of wild-type γHV68. This result contrasts with
the previous observation that inoculation with a gene 50
deficient γHV68 is not sufficient for protection (Moser et al.,
2006). It is conceivable that these distinct outcomes reflect
differences in presentation of viral antigens between the
replication-defective viruses used. Because herpesvirus repli-
cation is coordinated by a cascade of gene expression (Roizman,
1996), it would be expected that a virus deficient in an
immediate-early gene such as gene 50 would express fewer viral
genes than a virus deficient in an early gene such as that
encoding ssDNABP, and thus would provide less opportunity
for presentation of virus-encoded antigens for stimulation of an
antiviral immune response. In support of this concept, i.n.
infection with the gene 50 deficient γHV68 did not activate T
cells or B cells in the lung (Moser et al., 2006). Further work
will be necessary to determine whether specific antibody and T
cell responses are similar between wild-type γHV68 and
γHV68.ΔssDNABP infected mice. However, these data
strongly suggest that the γHV68.ΔssDNABP initiates an
immune response either to the presumably limited number of
lytic antigens expressed by the virus, to latent antigens, or to
both.
The results presented here are compatible with the
hypothesized role of latency in the physiology of γ-herpesvirus
infection-evading a primed immune system and thereby
providing an important reservoir for maintenance of the viral
genome. Coupled with the previous demonstrations that T cells
alter the number of cells latently infected with wild-type
γHV68, our observation that despite being sufficiently primed
to protect against wild-type virus infection, T and B cells do not
alter the number of cells carrying a virus deficient in lytic
replication suggests that latency is immunologically silent.DNABP. Plaque assay for splenic titer in mock-vaccinated or vaccinated B6 mice
(mock), 1000 TCID50 γHV68.ΔssDNABP, or 1000 PFU γHV68. Twenty-eight
ays, spleens were harvested, homogenized, and acute titers were determined by
led from two experiments, 8 mice total for i.n. challenge, 18 mice total for i.p.
217S.A. Tibbetts et al. / Virology 353 (2006) 210–219Thus, the expression of the full complement of lytic viral
antigens during the course of infection may be a requirement for
the adaptive immune response to effectively target cells that
carry latent genomes. Further work will be necessary to
determine whether proper priming of the immune response by
a broader array of lytic antigens is a requirement for targeting
latency antigens, or whether the lytic antigens themselves are
the primary target for immune control during chronic infection.
Materials and methods
Cells and viruses
Wild-type NIH 3T12 cells (3T12) and NIH 3T12 cells stably
expressing gene 6 (3T12.ORF6) were maintained in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10%
fetal calf serum, 100 U of penicillin per ml, 100 mg of
streptomycin per ml, and 2 mM L-glutamine (complete
DMEM). γHV68 clone WUMS (ATCC VR1465) was passaged
and titered by plaque assay on NIH 3T12 cells.
Mice and infections
C57BL/6J (B6) mice, and TCRβδ−/− and RAG-1−/− mice on
a B6 background were obtained from Jackson Laboratories (Bar
Harbor, ME), and were bred at Washington University School
of Medicine in accordance with all Federal and University
guidelines. Eight to twelve-week-old animals were used for all
experiments. Mice were infected i.p. with 1000 PFU γHV68 or
1000 TCID50 γHV68.ΔssDNABP diluted in 0.5 ml DMEM, or
i.n. with 1000 TCID50 γHV68.ΔssDNABP diluted in 25 μl
DMEM.
Construction of γHV68.ΔssDNABP
γHV68.ΔssDNABP was generated from the parental
γHV68 bacterial artificial chromosome (Adler et al., 2000), as
described in Results and Discussion. The γHV68 BAC was
generously provided by Ulrich Koszinowsk (University of
Munich, Germany). Following allelic exchange and selection,
the gene 6 locus from one of the correct clones was sequenced
to confirm the correct nucleotide structure of the mutation.
Limiting dilution nested PCR
To determine the frequency of cells carrying viral genome,
single-copy sensitivity nested PCR for γHV68.ΔssDNABP
was performed on serial dilutions of cells using a previously
published method (van Dyk et al., 2000; Weck et al., 1999;
Tibbetts et al., 2002, 2003a, 2003b). Briefly, frozen test cells
were thawed, washed, resuspended in an isotonic solution, and
counted. Starting at 104 cells/reaction, cells were serially diluted
threefold in a background of uninfected 3T12 cells such that 104
total cells were present in each well (10 μl total), and plated in a
96-well PCR plate at 12 wells/dilution. Single copies of
control plasmid (containing the gene 6 locus from the
γHV68.ΔssDNABP BAC) in a background of 3T12 cellswere included as positive controls. 3T12 samples with no
plasmid were included as negative controls. After overnight
lysis of cells with proteinase K, round one of PCR was
performed in 20 μl/reaction. Nested PCR was performed
following addition of 10 μl of round two reaction buffer to
the same well, and nested products were visualized on a 3%
agarose gel.
Vaccinations and plaque assays
Mice were vaccinated i.p. with 1000 pfu γHV68 or 1000
TCID γHV68.ΔssDNABP diluted in 0.5 ml DMEM, or were
mock-vaccinated with 3T12 cell lysate diluted in 0.5 ml
DMEM. Twenty-eight days later, mice were challenged i.p. with
1000 pfu γHV68 in 0.5 ml DMEM. At the end of the challenge
period, mice were sacrificed and organs from 3–5 mice per
group were harvested. Plaque assays were performed as
previously described (van Berkel et al., 2002; van Dyk et al.,
2000). Briefly, organs were harvested into sterile, screw-top 2-
ml tubes containing 1 ml of DMEM and 100 μl 1-mm zirconia/
silica beads (BioSpec Products Inc., Bartlesville, OK), and
stored at −80 °C. Samples were thawed on ice and homogenized
using a Mini BeadBeater (BioSpec), then further diluted in
DMEM prior to infecting 3T12 monolayers. Infected mono-
layers were overlayed with methylcellulose, and plaques were
visualized at day seven using neutral red staining. The limit of
detection was 50 PFU.
Acknowledgments
HWV was supported by NIH grant CA 74730 and AI 96511.
SAT was supported by a Leukemia and Lymphoma Society
Special Fellow award (3460-04). FS was supported by an
American Cancer Society Fellowship (PF-03-061-01-MBC).
ALS was supported by a Ruth L. Kirschstein National Research
Service Award, grant 5 T32 GM07200, and American Heart
Association grant 0515435Z. We thank members of the Virgin
laboratory for helpful discussions, and Darren Kreamalmeyer
for expert technical assistance with mouse strains. Special
thanks are given to Dr. Douglas Braaten without whom viral
mutants and complementing cells lines would not have been
possible to construct.
References
Adler, H., Messerle, M., Wagner, M., Koszinowski, U.H., 2000. Cloning and
mutagenesis of the murine gammaherpesvirus 68 genome as an infectious
bacterial artificial chromosome. J. Virol. 74, 6964–6974.
Adler, H., Messerle, M., Koszinowski, U.H., 2001. Virus reconstituted from
infectious bacterial artificial chromosome (BAC)-cloned murine gamma-
herpesvirus 68 acquires wild-type properties in vivo only after excision of
BAC vector sequences. J. Virol. 75, 5692–5696.
Augustinova, H., Hoeller, D., Yao, F., 2004. The dominant-negative herpes
simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective
vaccine against wild-type HSV-1 infection in mice. J. Virol. 78, 5756–5765.
Babcock, G.J., Decker, L.L., Freeman, R.B., Thorley-Lawson, D.A., 1999.
Epstein-Barr virus-infected resting memory B cells, not proliferating
lymphoblasts, accumulate in the peripheral blood of immunosuppressed
patients. J. Exp. Med. 190, 567–576.
218 S.A. Tibbetts et al. / Virology 353 (2006) 210–219Bayliss, G.J., Marsden, H.S., Hay, J., 1975. Herpes simplex virus proteins:
DNA-binding proteins in infected cells and in the virus structure. Virology
68, 124–134.
Braaten, D.C., Sparks-Thissen, R.L., Kreher, S., Speck, S.H., Virgin, H.W.,
2005. An optimized CD8+ T-cell response controls productive and latent
gammaherpesvirus infection. J. Virol. 79, 2573–2583.
Cardin, R.D., Brooks, J.W., Sarawar, S.R., Doherty, P.C., 1996. Progressive loss
of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of
CD4+ T cells. J. Exp. Med. 184, 863–871.
Christensen, J.P., Cardin, R.D., Branum, K.C., Doherty, P.C., 1999. CD4(+) T
cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is
mediated by IFN-gamma. Proc. Natl. Acad. Sci. 96, 5135–5140.
Clambey, E.T., Virgin, H.W., Speck, S.H., 2000. Disruption of the murine
gammaherpesvirus 68M1 open reading frame leads to enhanced reactivation
from latency. J. Virol. 74, 1973–1984.
Da Costa, X.J., Jones, C.A., Knipe, D.M., 1999. Immunization against genital
herpes with a vaccine virus that has defects in productive and latent
infection. Proc. Natl. Acad. Sci. U.S.A. 96, 6994–6998.
Ehtisham, S., Sunil-Chandra, N.P., Nash, A.A., 1993. Pathogenesis of murine
gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells.
J. Virol. 67, 5247–5252.
Fixman, E.D., Hayward, G.S., Hayward, S.D., 1992. trans-acting requirements
for replication of Epstein–Barr virus ori-Lyt. J. Virol. 66, 5030–5039.
Flano, E., Jia, Q., Moore, J., Woodland, D.L., Sun, R., Blackman, M.A., 2005.
Early establishment of gamma-herpesvirus latency: implications for immune
control. J. Immunol. 174, 4972–4978.
Gangappa, S., Kapadia, S.B., Speck, S.H., Virgin, H.W., 2002a. Antibody to a
lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-
deficient mice. J. Virol. 76, 11460–11468.
Gangappa, S., Van Dyk, L.F., Jewett, T.J., Speck, S.H., Virgin, H.W., 2002b.
Identification of the in vivo role of a viral bcl-2. J. Exp. Med. 195, 931–940.
Godowski, P.J., Knipe, D.M., 1986. Transcriptional control of herpesvirus gene
expression: gene functions required for positive and negative regulation.
Proc. Natl. Acad. Sci. U.S.A. 83, 256–260.
Grusby, M.J., Johnson, R.S., Papaioannou, V.E., Glimcher, L.H., 1991.
Depletion of CD4 T cells in major histocompatibility complex class II-
deficient mice. Science 253, 1417–1420.
Jia, Q.M., Wu, T.T., Liao, H.I., Chernishof, V., Sun, R., 2004. Murine
gammaherpesvirus 68 open reading frame 31 is required for viral replication.
J. Virol. 78, 6610–6620.
Kapadia, S.B., Molina, H., van, B.V., Speck, S.H., Virgin, H.W., 1999. Murine
gammaherpesvirus 68 encodes a functional regulator of complement
activation. J. Virol. 73, 7658–7670.
Karber, G., 1931. Beitrag zar Kollktiven Behandlung Pharmakologischer
Reiherersuche. Arch. Exp. Patho. Pharmakol. 162, 480–483.
Lee, C.K., Knipe, D.M., 1985. An immunoassay for the study of DNA-binding
activities of herpes simplex virus protein ICP8. J. Virol. 54, 731–738.
Littler, E., Purifoy, D., Minson, A., Powell, K.L., 1983. Herpes simplex virus
non-structural proteins: III. Function of the major DNA-binding protein.
J. Gen. Virol. 64, 983–995.
MacDonald, M.R., Li, X.Y., Stenberg, R.M., Campbell, A.E., Virgin, H.W.,
1998. Mucosal and parenteral vaccination against acute and latent murine
cytomegalovirus (MCMV) infection by using an attenuated MCMVmutant.
J. Virol. 72, 442–451.
McClellan, J.S., Tibbetts, S.A., Gangappa, S., Brett, K.A., Virgin, H.W., 2004.
Critical role of CD4 T cells in an antibody-independent mechanism of
vaccination against gamma-herpesvirus latency. J. Virol. 78, 6836–6845.
Mombaerts, P., Clarke, A.R., Rudnicki, M.A., Iacomini, J., Itohara, S., Lafaille,
J.J., Wang, L.L., Ichikawa, Y., Jaenisch, R., Hooper, M.L., Tonegawa, S.,
1992a. Mutations in T-cell antigen receptor genes alpha-block and beta-
block thymocyte development at different stages. Nature 360, 225–231.
Mombaerts, P., Iacomini, J., Johnson, R.S., Herrup, K., Tonegawa, S.,
Papaioannou, V.E., 1992b. RAG-1-deficient mice have no mature B and T
lymphocytes. Cell 68, 869–877.
Moorman, N.J., Lin, C.Y., Speck, S.H., 2004. Identification of candidate
gammaherpesvirus 68 genes required for virus replication by signature-
tagged transposon mutagenesis. J. Virol. 78, 10282–10290.
Morrison, L.A., Knipe, D.M., 1994. Immunization with replication-defectivemutants of herpes simplex virus type 1: sites of immune intervention in
pathogenesis of challenge virus infection. J. Virol. 68, 689–696.
Morrison, L.A., Knipe, D.M., 1997. Contributions of antibody and Tcell subsets
to protection elicited by immunization with a replication-defective mutant of
herpes simplex virus type 1. Virology 239, 315–326.
Moser, J.M., Farrell, M.L., Krug, L.T., Upton, J.W., Speck, S.H., 2006. A
gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in
the lung but fails to vaccinate against a wild-type virus challenge. J. Virol.
80, 1592–1598.
Nguyen, L.H., Knipe, D.M., Finberg, R.W., 1992. Replication-defective
mutants of herpes simplex virus (HSV) induce cellular immunity and
protect against lethal HSV infection. J. Virol. 66, 7067–7072.
Powell, K.L., Purifoy, D.J., 1976. DNA-binding proteins of cells infected by
herpes simplex virus type 1 and type 2. Intervirology 7, 225–239.
Roizman, B., 1996. The function of herpes simplex virus genes: a primer for
genetic engineering of novel vectors. Proc. Natl. Acad. Sci. U.S.A. 93,
11307–11312.
Simas, J.P., Bowden, R.J., Paige, V., Efstathiou, S., 1998. Four tRNA-like
sequences and a serpin homologue encoded by murine gammaherpesvirus
68 are dispensable for lytic replication in vitro and latency in vivo. J. Gen.
Virol. 79, 149–153.
Simas, J.P., Swann, D., Bowden, R., Efstathiou, S., 1999. Analysis of murine
gammaherpesvirus-68 transcription during lytic and latent infection. J. Gen.
Virol. 80, 75–82.
Smith, G.A., Enquist, L.W., 1999. Construction and transposon mutagenesis in
Escherichia coli of a full-length infectious clone of pseudorabies virus, an
alphaherpesvirus. J. Virol. 73, 6405–6414.
Song, M.J., Hwang, S.M., Wong, W.H., Wu, T.T., Lee, S.M., Liao, H.I., Sun, R.,
2005. Identification of viral genes essential for replication of murine gamma-
herpesvirus 68 using signature-tagged mutagenesis. Proc. Natl. Acad. Sci.
U. S. A. 102, 3805–3810.
Sparks-Thissen, R.L., Braaten, D.C., Kreher, S., Speck, S.H., Virgin, H.W.,
2004. An optimized CD4 T-cell response can control productive and latent
gammaherpesvirus infection. J. Virol. 78, 6827–6835.
Stevenson, P.G., Cardin, R.D., Christensen, J.P., Doherty, P.C., 1999.
Immunological control of a murine gammaherpesvirus independent of
CD8+ T cells. J. Gen. Virol. 80 (Pt. 2), 477–483.
Stevenson, P.G., May, J.S., Smith, X.G., Marques, S., Adler, H., Koszinowski,
U.H., Simas, J.P., Efstathiou, S., 2002. K3-mediated evasion of CD8(+) T
cells aids amplification of a latent gamma-herpesvirus. Nat. Immunol. 3,
733–740.
Sunil-Chandra, N.P., Efstathiou, S., Nash, A.A., 1992. Murine gammaherpes-
virus 68 establishes a latent infection in mouse B lymphocytes in vivo.
J. Gen. Virol. 73, 3275–3279.
Tibbetts, S.A., Van Dyk, L., Speck, S.H., Virgin, H.W., 2002. Immune control of
the number and reactivation phenotype of cells latently infected with a
gamma-herpesvirus. J. Virol. 76, 7125–7132.
Tibbetts, S.A., Loh, J., van, B.V., McClellan, J.S., Jacoby, M.A., Kapadia, S.B.,
Speck, S.H., Virgin, H.W., 2003a. Establishment and maintenance of
gammaherpesvirus latency are independent of infective dose and route of
infection. J. Virol. 77, 7696–7701.
Tibbetts, S.A., McClellan, J.S., Gangappa, S., Speck, S.H., Virgin, H.W., 2003b.
Effective vaccination against long-term gammaherpesvirus latency. J. Virol.
77, 2522–2529.
Usherwood, E.J., Roy, D.J., Ward, K., Surman, S.L., Dutia, B.M., Blackman,
M.A., Stewart, J.P., Woodland, D.L., 2000. Control of gammaherpesvirus
latency by latent antigen-specific CD8(+) T cells. J. Exp. Med. 192,
943–952.
van Berkel, V., Levine, B., Kapadia, S.B., Goldman, J.E., Speck, S.H., Virgin,
H.W., 2002. Critical role for a high affinity chemokine binding protein in
lethal meningitis caused by a g-herpesvirus. J. Clin. Invest. 109 (7),
905–914 (April 1).
Van Dyk, L.F., Virgin, H.W., Speck, S.H., 2000. The murine gammaherpesvirus
68 v-cyclin is a critical regulator of reactivation from latency. J. Virol. 74,
7451–7461.
van Parijs, L., Refaeli, Y., Lord, J.D., Nelson, B.H., Abbas, A.K., Baltimore, D.,
1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival,
and Fas-mediated activation-induced cell death. Immunity 11, 281–288.
219S.A. Tibbetts et al. / Virology 353 (2006) 210–219Weck, K.E., Barkon, M.L., Yoo, L.I., Speck, S.H., Virgin, H.W., 1996.
Mature B cells are required for acute splenic infection, but not for
establishment of latency, by murine gammaherpesvirus 68. J. Virol. 70,
6775–6780.
Weck, K.E., Kim, S.S., Virgin, H.W., Speck, S.H., 1999. B cells regulate murine
gammaherpesvirus 68 latency. J. Virol. 73, 4651–4661.
Weibel, R.E., Neff, B.J., Kuter, B.J., Guess, H.A., Rothenberger, C.A.,
Fitzgerald, A.J., Connor, K.A., McLean, A.A., Hilleman, M.R., Buynak,E.B., 1984. Live attenuated varicella virus vaccine. Efficacy trial in healthy
children. N. Engl. J. Med. 310, 1409–1415.
Weller, S.K., Lee, K.J., Sabourin, D.J., Schaffer, P.A., 1983. Genetic analysis of
temperature-sensitive mutants which define the gene for the major herpes
simplex virus type 1 DNA-binding protein. J. Virol. 45, 354–366.
Wu, T.T., Usherwood, E.J., Stewart, J.P., Nash, A.A., Sun, R., 2000. Rta of
murine gammaherpesvirus 68 reactivates the complete lytic cycle from
latency. J. Virol. 74, 3659–3667.
